Tecovirimat

DRUG6 trials

Sponsors

U.S. Army Medical Research and Development Command, SIGA Technologies, Marina Klein, ANRS, Emerging Infectious Diseases

Conditions

MonkeypoxMpoxSmallpox

Phase 2

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

Active, not recruitingNCT04957485

SIGA TechnologiesSmallpox

Start: 2022-04-05End: 2027-01-01Updated: 2026-09-14

Phase 3

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

CompletedNCT02474589

SIGA TechnologiesSmallpox

Start: 2015-06-19End: 2016-08-24Updated: 2026-09-11

Tecovirimat in Non-hospitalized Patients With Monkeypox

SuspendedNCT05534165

Marina KleinMonkeypox

Start: 2023-08-14End: 2026-03-31Target: 120Updated: 2026-03-04

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

Active, not recruitingNCT05597735

ANRS, Emerging Infectious DiseasesMonkeypox, Mpox

Start: 2023-03-03End: 2026-09-30Target: 480Updated: 2026-05-26

Phase 4

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

CompletedNCT04485039

SIGA TechnologiesSmallpox

Start: 2022-06-08End: 2023-04-23Updated: 2026-09-11

Unknown Phase

Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

U.S. Army Medical Research and Development CommandMonkeypox, Smallpox

Updated: 2026-07-06

Related Papers

MOSAIC: A cohort study of human mpox virus disease.

2023-12-122 citations

Comprehensive literature review of monkeypox.

2022-12-0161 citations

Intersecting HIV and mpox epidemics: more questions than answers

Journal of the International AIDS Society2022-12-0116 citations

Oral Tecovirimat for the Treatment of Smallpox

New England Journal of Medicine2018-07-04403 citations